Murchinson’s BioXcel Therapeutics BTAI Stock Holding History

Murchinson’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-80,618	Closed	-$146K	–	101
2025 Q2	$146K	Sell	80,618 -55,458	-41%	-$91.8K	0.05%	58
2025 Q1	$276K	Buy	+136,076	New	+$508K	0.01%	76

Other funds holding BTAI

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

OCM

Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

OFA

Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return

Murchinson's BTAI Position: Q3 2025 in Review

Murchinson sold out of BioXcel Therapeutics (BTAI) in Q3 2025, closing a stake of 80,618 shares — an estimated $146K sold.

Murchinson first reported a position in BTAI in Q1 2025 and held it in 2 quarters. The position peaked at $276K in Q1 2025. 35 funds tracked by Wall St. Rank hold BTAI as of Q3 2025.

Murchinson reported no remaining BioXcel Therapeutics position as of Q3 2025 after selling out during the quarter.
Murchinson sold 80,618 BioXcel Therapeutics shares in Q3 2025, an estimated $146K.
Murchinson first reported a position in BioXcel Therapeutics in Q1 2025 and held it in 2 quarters.
Murchinson's BioXcel Therapeutics position peaked at $276K in Q1 2025.
35 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q3 2025.

Based on Murchinson's 13F filing for Q3 2025, filed 14 Nov 2025.